Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C23H32N2O3S |
Molecular Weight | 416.577 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])CC5=NN(C=C5C[C@]34C)S(C)(=O)=O
InChI
InChIKey=MHDDZDPNIDVLNK-ZGIWMXSJSA-N
InChI=1S/C23H32N2O3S/c1-5-23(26)11-9-19-17-7-6-16-12-20-15(14-25(24-20)29(4,27)28)13-21(16,2)18(17)8-10-22(19,23)3/h1,14,16-19,26H,6-13H2,2-4H3/t16-,17+,18-,19-,21-,22-,23-/m0/s1
Molecular Formula | C23H32N2O3S |
Molecular Weight | 416.577 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P10275 Gene ID: 367.0 Gene Symbol: AR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/2615358 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7543598
Zanoterone (100 to 800 mg.) versus placebo was studied in 463 patients with benign prostatic hyperplasia
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:30:14 GMT 2023
by
admin
on
Fri Dec 15 15:30:14 GMT 2023
|
Record UNII |
XQ5V1W49JG
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C242
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
107000-34-0
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY | |||
|
Zanoterone
Created by
admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
|
PRIMARY | |||
|
C74123
Created by
admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
|
PRIMARY | |||
|
C060492
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY | |||
|
CC-68
Created by
admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
|
PRIMARY | |||
|
DTXSID50147873
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY | |||
|
XQ5V1W49JG
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908363
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY | |||
|
100000079370
Created by
admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
|
PRIMARY | |||
|
9844827
Created by
admin on Fri Dec 15 15:30:15 GMT 2023 , Edited by admin on Fri Dec 15 15:30:15 GMT 2023
|
PRIMARY | |||
|
6926
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY | |||
|
SUB00139MIG
Created by
admin on Fri Dec 15 15:30:14 GMT 2023 , Edited by admin on Fri Dec 15 15:30:14 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |